No Result
View All Result
  • Login
  • Register
Business & Technology
SUBSCRIBE
  • .
  • Thought Leadership
  • Conversations
  • International Voices
  • News
  • Wealth
  • Digital Transformation
  • Lifestyle
  • Videos
  • Podcasts
  • .
  • Thought Leadership
  • Conversations
  • International Voices
  • News
  • Wealth
  • Digital Transformation
  • Lifestyle
  • Videos
  • Podcasts
No Result
View All Result
Biztech Asia
Home News

Pfizer to supply 12.8 million doses of Covid-19 vaccine to Malaysia

by editorial
27/11/20
in News
2 min read
0
Vaccines breakthroughs call for cautious optimism

Putrajaya has inked a deal with Pfizer to obtain Covid-19 vaccines for 20% of the Malaysian population starting next year.

Prime Minister Tan Sri Muhyiddin Yassin said the government had, on Nov 24, signed a preliminary purchasing agreement (perjanjian pembelian awal) of 12.8 million doses to immunise 6.4 million Malaysians.

Through the agreement, Pfizer has agreed to deliver one million doses in the first quarter of next year, followed by 1.7 million doses in the second quarter, 5.8 million in the third quarter and 4.3 million doses in the fourth quarter.

The prime minister said the vaccination will be conducted in phases and will prioritise high-risk groups who are more susceptible to Covid-19. High risk groups, including frontline workers, the elderly, and patients with non-communicable diseases such as heart disease, diabetes, chronic respiratory diseases and others, would be the first to be vaccinated before it is expanded to other target groups.

“The agreement with Pfizer is to ensure that the government has data access to evaluate vaccine quality, safety, and efficacy, apart from ensuring access to the vaccine once it is distributed by the company.

“Pfizer has reported that their primary interim data showed a vaccine efficacy of 95%, however, the company still needs the approval of the United States’ Food and Drug Administration (FDA) and regulatory approval from the producing country, in addition to obtaining approval from our Health Ministry’s National Pharmaceutical Regulatory Agency (NPRA) before it can be used in Malaysia,” Muhyiddin said.

Furthermore, the Health Ministry, also signed an agreement with the vaccine development platform Covax Facility to obtain Covid-19 vaccines to immunise 10% of Malaysians. Muhyiddin said both agreements therefore are expected to guarantee Covid-19 vaccine access for 30% of Malaysians.

“The Health Ministry, together with the Science, Technology and Innovation Ministry, are in active discussion with companies worldwide to gain enough access to the Covid-19 vaccine for Malaysians,” he said.

He also announced that the Health Ministry would begin a phase three vaccine clinical research through a government-to-government initiative with China, with the vaccine being developed by the republic’s Institute of Medical Biology Chinese Academy of Medical Sciences (IMBCAMS).

A total of 3,000 participants would be involved in the clinical research, and an evaluation would be done on the safety and efficacy of the developed vaccine. The study, which is expected to start in Dec 2020, will be conducted by the local clinical research organisation, and has been registered in the National Medical Research Register.

“The vaccine safety profile will be first reviewed by the NPRA to obtain the Clinical Trial Import License, and will be studied by the Medical Research and Ethics Committee to ensure that the study is conducted in accordance with Health Ministry guidelines,” the prime minister explained, adding that this initiative would involve eight clinical research centres under the Health Ministry.

“The government expresses its highest appreciation to the IMBCAMS which will be collaborating with us to conduct the phase three clinical research in Malaysia.

“The government also provides its assurance to all Malaysians that that the vaccines used in Malaysia must meet the strict conditions set by the NPRA, we will never compromise on this,” he emphasised.

 

Previous Post

Malaysia-China relations on the right path

Next Post

How Covid-19 has rewritten the rules of recruitment?

editorial

editorial

Related Posts

Malaysia’s Catcha to raise USD250 million in US IPO
News

Malaysia’s Catcha to raise USD250 million in US IPO

Vaccines rollouts will power global economic growth in 2021: IMF
News

Vaccines rollouts will power global economic growth in 2021: IMF

Australia calls to mend ties with China
News

Australia calls to mend ties with China

Janet Yellen, the first female US treasury chief
News

Janet Yellen, the first female US treasury chief

US dollar versus rising treasury yields; gold on the defensive
News

US stocks in the green despite volatile session

China picks up speed, overtakes US as largest recipient of FDI
News

China picks up speed, overtakes US as largest recipient of FDI

Next Post
How Covid-19  has rewritten the rules of recruitment?

How Covid-19 has rewritten the rules of recruitment?

Former Zappos CEO, Tony Hsieh, dies at 46

Former Zappos CEO, Tony Hsieh, dies at 46

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

I agree to the Terms & Conditions and Privacy Policy.

Recommended Stories

Optimism amid new focus on sustainable investing

Optimism amid new focus on sustainable investing

MDEC appoints new chief financial officer

MDEC appoints new chief financial officer

The perverse tyranny of ultra-low rates to productivity

The perverse tyranny of ultra-low rates to productivity

Popular Stories

  • Economic recovery: an elusive thought?

    Economic recovery: an elusive thought?

    0 shares
    Share 0 Tweet 0
  • Cannibalising your business can be profitable

    0 shares
    Share 0 Tweet 0
  • Sexual fulfillment builds confidence and well-being

    0 shares
    Share 0 Tweet 0
  • Tech Stocks – Ant gets stomped on but REITS offer stability amid volatility

    0 shares
    Share 0 Tweet 0
  • Singapore REITS and China tech stocks – Which should you buy?

    0 shares
    Share 0 Tweet 0

About Us

A Business and Technology digital publication that engages business leaders in business and technology conversations to help everyone pivot, adapt, and thrive in these turbulent times.

LEARN MORE »

Contact Us

Phone: 016-2011 050

Email: editor@biztech.asia

Address:
Level 18, Boutique Office 1 (B01-C)
Menara 2, No. 3, Jalan Bangsar,
KL Eco City, 59200, Kuala Lumpur.

Email Newsletter

Loading

© 2020 Business & Technology - made possible by Milestones Digital.

No Result
View All Result
  • Home
  • Thought Leadership
  • Conversations
  • International Voices
  • News
  • Wealth
  • Digital Transformation
  • Lifestyle
  • Videos
  • Podcasts
  • Login
  • Sign Up

© 2020 Business & Technology - made possible by Milestones Digital.

Welcome Back!

Sign In with Facebook
Sign In with Google
OR

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Sign Up with Facebook
Sign Up with Google
OR

Fill the forms bellow to register

*By registering into our website, you agree to the Terms & Conditions and Privacy Policy.
All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.
Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

will use the information you provide on this form to be in touch with you and to provide updates and marketing.